Novo Nordisk A/S (NYSE:NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with Hims’ compounded semaglutide products for the U.S. market.
Novo Nordisk’s Legal Move Explained
Novo Nordisk, in its press release, said Hims & Hers engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.
Hims continues to unlawfully mass compound injectable versions, made with inauthentic API, and these knock-offs are putting patient health and well-being at risk, Novo claims.
Mass marketing by Hims and compounding pharmacies has flooded the market with knock-off Wegovy and Ozempic. Compounded semaglutide products may contain dangerous impurities or incorrect amounts of active ingredients, which can result in life-threatening immune responses, hospitalization, severe drug-drug interactions, and overdoses.
Impurity Levels In Compounded Drugs
According to Novo Nordisk’s testing, injectable semaglutide drugs compounded by pharmacies were found to contain impurities of up to 86%, with compounded oral semaglutide drugs containing impurities as high as 75%.
Even in small quantities, such impurities can negatively impact the safety and efficacy of a drug product, including unwanted immune responses like anaphylactic shock.
Price Action: NVO stock is up 6.84% at $50.90, and HIMS stock is down 26.93% at $16.83 at the last check on Monday, according to Benzinga Pro.
Photo by Tobias Arhelger via Shutterstock
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.